Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, ARS Pharmaceuticals Inc’s stock clocked out at $12.60, down -4.18% from its previous closing price of $13.15. In other words, the price has decreased by -$4.18 from its previous closing price. On the day, 2.42 million shares were traded. SPRY stock price reached its highest trading level at $13.2 during the session, while it also had its lowest trading level at $12.31.
Ratios:
To gain a deeper understanding of SPRY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.94 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 95.25. For the most recent quarter (mrq), Quick Ratio is recorded 14.04 and its Current Ratio is at 14.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $30.
On February 10, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $40.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 20 ’25 when Karas Eric sold 10,000 shares for $14.00 per share. The transaction valued at 140,000 led to the insider holds 7,696 shares of the business.
ERIC KARAS bought 10,000 shares of SPRY for $140,000 on Mar 20 ’25. On Mar 06 ’25, another insider, Shawver Laura, who serves as the Director of the company, sold 49,600 shares for $11.21 each. As a result, the insider received 556,046 and left with 210,346 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 1290277888 and an Enterprise Value of 991712512. As of this moment, ARS’s Price-to-Earnings (P/E) ratio for their current fiscal year is 164.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.87 while its Price-to-Book (P/B) ratio in mrq is 4.81. Its current Enterprise Value per Revenue stands at 11.124 whereas that against EBITDA is -330.131.
Stock Price History:
The Beta on a monthly basis for SPRY is 0.91, which has changed by 0.32028115 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, SPRY has reached a high of $18.51, while it has fallen to a 52-week low of $7.55. The 50-Day Moving Average of the stock is 3.97%, while the 200-Day Moving Average is calculated to be 2.10%.
Shares Statistics:
It appears that SPRY traded 1.56M shares on average per day over the past three months and 2556340 shares per day over the past ten days. A total of 97.95M shares are outstanding, with a floating share count of 51.79M. Insiders hold about 47.22% of the company’s shares, while institutions hold 50.53% stake in the company. Shares short for SPRY as of 1741910400 were 19429266 with a Short Ratio of 12.46, compared to 1739491200 on 16483868. Therefore, it implies a Short% of Shares Outstanding of 19429266 and a Short% of Float of 37.04.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
